Glucose-Lowering Agents in the Management of Nonalcoholic Fatty Liver Disease.

Author: Hyekyung YANG ¹ ; Cheol Young PARK
Author Information

1. Medical Research Institute, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea. cydoctor@chol.com
Publication Type:Original Article
Keywords: Diabetes mellitus; Glucose-lowering agents; Incretins; Nonalcoholic fatty liver disease; Sodium-glucose transporter 2; Thiazolidinediones
MeSH: Blood Glucose; Diabetes Mellitus; Diet; Disease Progression; Humans; Incretins; Life Style; Non-alcoholic Fatty Liver Disease*; Sodium-Glucose Transporter 2; Thiazolidinediones; Weight Loss
From:Journal of Korean Diabetes 2018;19(2):88-96
CountryRepublic of Korea
Language:Korean
Abstract: Nonalcoholic fatty liver disease (NAFLD) is more prevalent in diabetic patients than in non-diabetic subjects, because the two diseases share a common pathophysiological mechanism. Associated abnormalities can be observed from the pre-diabetic stage. Lifestyle intervention, including diet, exercise, and weight loss, is the primary recommended therapy for NAFLD. Among the therapeutic drugs for NAFLD treatment, anti-diabetic agents are aimed at improving or slowing the progression of NAFLD in addition to lowering blood glucose. In this paper, we systemically review the evidence surrounding antidiabetic medications and their ability to improve disease progression in patients with NAFLD.